Borealis Biosciences raised $150 million in Series A financing led by Versant Ventures and Novartis to develop next-generation RNA therapeutics for kidney diseases.
Borealis Biosciences raised $150 million in Series A financing led by Versant Ventures and Novartis to develop next-generation RNA therapeutics for kidney diseases.
08/22/24, 12:05 PM
Location
vancouverMoney raised
$150 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Novartis Ag, Versant Ventures
Borealis Biosciences emerged from stealth today with $150 million in combined Series A financing from Versant Ventures and Novartis AG. The funding will support the company's mission to address major unmet needs for patients with kidney diseases through RNA therapeutics.
Company Info
Location
vancouver, british columbia, canada
Additional Info
Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.